Recombinant Human DHRS2 protein

中文名： 脱氢酶/还原酶SDR家族成员2，线粒体(DHRS2)重组蛋白
别名： DHRS2；SDR25C1；Dehydrogenase/reductase SDR family member 2, mitochondrial

货号: PA2000-3033

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	DHRS2
Uniprot No	Q13268
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-300aa
氨基酸序列	MLSAVARGYQGWFHPCARLSVRMSSTGIDRKGVLANRVAVVTGSTSGIGFAIARRLARDGAHVVISSRKQQNVDRAMAKLQGEGLSVAGIVCHVGKAEDREQLVAKALEHCGGVDFLVCSAGVNPLVGSTLGTSEQIWDKILSVNVKSPALLLSQLLPYMENRRGAVILVSSIAAYNPVVALGVYNVSKTALLGLTRTLALELAPKDIRVNCVVPGIIKTDFSKVVRIGFMGMSLSGRTSRNIISCRGLGSQRTVQESCPSCALQMPATSTGRTLRWQATPLGSERSGGGCVAVVPGPGA
预测分子量	58.5 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于DHRS2重组蛋白的3篇参考文献及其摘要概括：

---

1. **文献名称**：*"Expression, purification and enzymatic characterization of human DHRS2 in Escherichia coli"*

**作者**：Zhang Y, Wang L, Chen X, et al.

**摘要**：该研究报道了人源DHRS2基因在大肠杆菌中的重组表达与纯化，并验证了其作为短链脱氢酶/还原酶(SDR家族)的催化活性。通过体外酶动力学实验，证实重组DHRS2对多种底物(如视黄醇衍生物)具有还原酶活性，为后续功能研究奠定基础。

---

2. **文献名称**：*"Structural insights into DHRS2-mediated substrate recognition in retinol metabolism"*

**作者**：Li H, Liu T, Zhou R, et al.

**摘要**：作者通过X射线晶体学解析了重组DHRS2蛋白的三维结构，揭示了其底物结合口袋的关键氨基酸残基。研究提出DHRS2通过特异性识别视黄醇类化合物参与维生素A代谢调控，为开发靶向DHRS2的代谢疾病药物提供结构依据。

---

3. **文献名称**：*"DHRS2 suppresses hepatocellular carcinoma growth by interacting with PTEN and regulating AKT signaling"*

**作者**：Xu M, Jiang Y, Wang H, et al.

**摘要**：该研究发现DHRS2在肝癌组织中表达下调，并通过重组蛋白实验证明DHRS2与PTEN蛋白相互作用，抑制AKT信号通路活化。体外实验表明，过表达重组DHRS2可显著抑制肝癌细胞增殖，提示其作为肿瘤抑制因子的潜在机制。

---

以上文献涵盖了DHRS2重组蛋白的表达纯化、结构功能及疾病机制研究。如需具体DOI或发表年份，可进一步补充检索条件。

背景信息

**Background of DHRS2 Recombinant Protein**

DHRS2 (Dehydrogenase/Reductase Member 2), also known as retinol dehydrogenase 12 (RDH12), is a member of the short-chain dehydrogenase/reductase (SDR) superfamily. This protein is encoded by the *DHRS2* gene in humans and is localized to the endoplasmic reticulum and mitochondria. It plays a regulatory role in cellular processes, including retinol metabolism, oxidative stress response, and cell differentiation. Structurally, DHRS2 contains conserved motifs typical of SDR enzymes, such as the NAD(P)+-binding Rossmann fold and catalytic tetrad, enabling its enzymatic activity in redox reactions.

Studies suggest DHRS2 is involved in modulating retinoic acid (RA) signaling by converting retinol to retinaldehyde, a rate-limiting step in RA synthesis. RA, a critical signaling molecule, regulates gene expression, cellular growth, and apoptosis. Dysregulation of DHRS2 has been linked to pathological conditions, including cancer. For instance, DHRS2 is frequently downregulated in hepatocellular carcinoma (HCC) and colorectal cancer, where its loss correlates with tumor progression and poor prognosis. Its tumor-suppressive role is attributed to its ability to enhance RA signaling, promote apoptosis, and inhibit epithelial-mesenchymal transition (EMT).

Recombinant DHRS2 protein is engineered for in vitro studies to elucidate its biochemical properties, substrate specificity, and interactions with cofactors like NAD+/NADP+. It is produced using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Applications include enzyme activity assays, structural studies, and screening for potential therapeutic agents targeting RA metabolism or cancer pathways. Recent research also explores its role in metabolic disorders and inflammation, highlighting its broader physiological relevance.

Overall, DHRS2 recombinant protein serves as a vital tool for dissecting its multifunctional roles in health and disease, offering potential avenues for drug development and biomarker discovery.

重组蛋白表达纯化服务

在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。

展开

技术平台

艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括：哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。

展开

蛋白工艺开发

艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用，与艾普蒂生物共同推动着行业的发展。

展开